| Solid state forms of lumateperone ditosylate salt |
2023-8-14 |
2023-11-30 |
|
| Identifying nerve condition using image analysis |
2023-7-28 |
2024-2-01 |
|
| Medical injection device packaging |
2023-5-07 |
2023-9-28 |
|
| Treating refractory migraine |
2023-2-17 |
2023-8-03 |
|
| Injection spring for aged prefilled syringe and auto injector |
2022-12-12 |
2023-5-25 |
|
| Selective p2x3 modulators |
2022-9-14 |
2023-8-10 |
|
| Inhaler system |
2022-8-26 |
2022-12-22 |
|
| S1P3 Antagonists |
2022-8-03 |
2022-12-22 |
|
| Inhaler system |
2022-7-14 |
2022-11-03 |
|
| Medroxyprogesterone acetate injectable compositions and methods of use |
2022-6-17 |
2022-12-08 |
|
| Medical device packaging |
2022-6-13 |
2022-12-22 |
|
| Drug delivery device with electronics |
2022-5-03 |
2022-8-18 |
|
| Retentive devices for gastrointestinal tract |
2022-3-02 |
2022-9-09 |
|
| Devices and methods for regio-specific drug release at ileocecal region |
2022-2-24 |
2022-4-01 |
|
| Fixed-dose pharmaceutical compositions |
2022-2-23 |
2024-1-03 |
|
| Expandable gastroretentive dosage form |
2021-12-07 |
2022-6-30 |
|
| Inhaler System |
2021-10-20 |
2022-5-12 |
|
| Drug delivery device with electronics and power management |
2021-10-14 |
2022-3-03 |
|
| Medroxyprogesterone acetate injectable compositions and methods of use |
2021-9-30 |
2022-2-17 |
|
| Devices and methods for gastric retentive drug delivery |
2021-8-27 |
2023-8-31 |
|
| Treatment of ocular inflammatory diseases using laquinimod |
2021-8-27 |
2021-12-16 |
|
| Devices for regio-specific release of carried drug at ileocecal region |
2021-8-27 |
2023-4-01 |
|
| Use of rasagiline for the treatment of restless legs syndrome |
2021-8-11 |
2021-12-16 |
|
| Inhaler system |
2021-7-02 |
2022-1-06 |
|
| Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat |
2021-5-04 |
2021-5-27 |
|
| Inhaler system |
2021-5-03 |
2021-6-16 |
|
| Pyrimidinone derivatives as cdc7 inhibitors |
2021-4-29 |
2022-3-17 |
|
| Preventing, treating, and reducing (persistent) post-traumatic headache |
2021-4-05 |
2022-2-17 |
|
| Process for manufacturing glatiramer acetate product |
2020-9-24 |
2021-9-30 |
|
| Drug delivery formulations |
2020-9-11 |
2022-10-20 |
|
| Inhaler system |
2020-8-21 |
2020-10-07 |
|
| Inhaler system |
2020-8-04 |
2020-9-16 |
|
| Inhaler system |
2020-7-02 |
2022-8-23 |
2022-8-23 |
| Inhaler system |
2020-6-19 |
2021-12-23 |
|
| Method and an apparatus for feeding a filament and use of the apparatus for … |
2020-2-04 |
2020-3-31 |
|
| Inhaler system |
2019-12-20 |
2020-2-05 |
|
| Inhaler system |
2019-12-20 |
2020-2-05 |
|
| Inhaler system |
2019-12-20 |
2020-2-05 |
|
| Pharmaceutical compositions for an anti-CGRP antagonist antibody |
2019-9-12 |
2021-1-26 |
2021-1-26 |
| Medroxyprogesterone acetate injectable compositions and methods of use |
2019-9-06 |
2022-4-07 |
|
| Analogs of pridopidine, their preparation and use |
2019-8-08 |
2020-1-30 |
|
| Inhaler system |
2019-7-29 |
2019-9-11 |
|
| Treating cluster headache |
2019-5-15 |
2020-4-02 |
|
| Inhaler system |
2019-4-30 |
2019-6-12 |
|
| Solid state forms of relugolix |
2019-3-14 |
2021-1-20 |
|
| Nasal spray device |
2019-2-21 |
2019-5-03 |
|
| Combination of laquinimod and pridopidine for treating neurodegenerative … |
2018-12-18 |
2019-4-25 |
|
| Long acting gastric residence system |
2018-12-03 |
2021-12-02 |
|
| Solid state forms of spiro-oxindole compounds |
2018-10-10 |
2019-3-07 |
|
| Salt and solid state forms of escitalopram |
2018-10-09 |
2022-7-19 |
2022-7-19 |
| Method for particle size reduction |
2018-9-27 |
2019-4-04 |
|
| Method for manufacture of inhalation powders |
2018-9-22 |
2019-3-28 |
|
| Dry powder inhalable medicament comprising glycopyrronium |
2018-9-20 |
2019-3-28 |
|
| Inhalable medicament |
2018-9-20 |
2019-3-28 |
|
| Re-useable injector device for syringe |
2018-8-09 |
2018-12-06 |
|
| Additively manufactured controlled release dosage forms |
2018-7-30 |
2019-2-07 |
|
| Use of laquinimod to delay huntington's disease progression |
2018-7-05 |
2018-11-01 |
|
| Drug Repurposing Hypothesis Generation Using Clinical Drug-Drug Interaction … |
2018-7-03 |
2020-1-09 |
|
| Transdermal dosage form |
2018-7-02 |
2019-9-10 |
2019-9-10 |
| Automatic Generation of User and Non-User Cohorts for The Estimation of Drug's … |
2018-6-28 |
2020-1-02 |
|
| Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis … |
2018-5-02 |
2019-1-03 |
|
| Solid state forms of midostaurin |
2018-3-06 |
2020-1-15 |
|
| Solid state forms of netarsudil mesylate |
2018-2-01 |
2018-8-02 |
|
| Treatment of lupus nephritis using laquinimod |
2018-1-22 |
2018-5-24 |
|
| Treatment of Glaucoma Using Laquinimod |
2018-1-19 |
2018-5-24 |
|
| Pre-filled syringe |
2018-1-11 |
2021-3-17 |
2021-3-17 |
| Topical detomidine formulations |
2018-1-05 |
2019-11-14 |
|
| Treatment of multiple sclerosis with combination of laquinimod and dimethyl … |
2018-1-04 |
2018-2-01 |
|
| 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, … |
2018-1-04 |
2018-5-24 |
|
| Antibody variants transmigrating the blood-brain barrier and uses thereof |
2017-12-12 |
2019-10-16 |
|
| Gastric residence system |
2017-12-04 |
2020-8-11 |
2020-8-11 |
| Treatment of progressive forms of multiple sclerosis with laquinimod |
2017-11-13 |
2018-3-08 |
|
| Preparation of a glatiramer acetate drug product |
2017-11-09 |
2017-12-27 |
|
| Treatment of Crohn's disease with laquinimod |
2017-10-30 |
2017-11-16 |
|
| Treatment of inflammatory bowel disease with 6-mercaptopurine |
2017-10-16 |
2017-12-31 |
|
| Solid state forms of sotagliflozin |
2017-10-05 |
2018-4-12 |
|
| Treatment of crohn's disease with delayed-release 6-mercaptopurine |
2017-9-28 |
2018-1-18 |
|
| 2-oxo-1,2-dihydro-quinoline modulators of immune function |
2017-9-27 |
2018-3-29 |
|
| Preparation and uses of pyrimidinone derivative |
2017-9-22 |
2020-4-23 |
|
| Gene expression characterization of a glatiramer acetate related drug product … |
2017-9-14 |
2018-3-22 |
|
| Treatment of multiple sclerosis with laquinimod |
2017-9-11 |
2018-2-15 |
|
| Deuterium-Substituted Oxazepin Compounds |
2017-9-07 |
2018-3-08 |
|
| Medroxyprogesterone acetate injectable compositions and methods of use |
2017-9-07 |
2020-7-15 |
|
| Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
2017-8-09 |
2017-8-31 |
|
| Treatment Of Neurodegenerative Diseases With Combination Of Laquinimod And … |
2017-8-04 |
2017-12-14 |
|
| Crystals of laquinimod sodium and improved process for the manufacture thereof |
2017-8-01 |
2017-11-16 |
|
| Use of high dose laquinimod for treating multiple sclerosis |
2017-7-21 |
2017-12-21 |
|
| N-ethyl-n-phenyl-1,2-dihydro-4,5-dihydroxy-1-methyl-2-oxo-3- … |
2017-7-14 |
2018-1-18 |
|
| Laquinimod Combination Therapy For Treatment Of Multiple Sclerosis |
2017-7-06 |
2017-10-26 |
|
| Use of laquinimod for treating crohn's disease patients who failed first-line … |
2017-6-26 |
2017-10-12 |
|
| Asymmetric synthesis of funapide |
2017-6-16 |
2018-10-16 |
2018-10-16 |
| A method, system and program for improved health care |
2017-6-16 |
2017-7-06 |
|
| Laquinimod for reducing thalamic damage in multiple sclerosis |
2017-6-08 |
2017-6-29 |
|
| Treatment of multiple sclerosis with laquinimod |
2017-5-28 |
2017-7-31 |
|
| Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) … |
2017-5-24 |
2017-12-22 |
|
| Treatment of multiple sclerosis with combination of laquinimod and a statin |
2017-5-22 |
2017-7-31 |
|
| Inhalable formulation |
2017-5-12 |
2017-9-20 |
|
| Dry powder formulation |
2017-5-12 |
2017-9-20 |
|
| Pharmaceutical compositions of memantine |
2017-5-01 |
2017-8-17 |
|
| Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2- … |
2017-4-05 |
2017-6-29 |
|